AVITA Medical Surges Toward Cash Flow Break-even | Business and Finance News

AVITA Medical is on a rocket ship—crushing Q2 revenue with $21.7M, up 18% YoY and 13% sequentially, fueled by RECELL’s U.S. dominance and global expansion of RECELL GO in Europe, UK, and Australia. Cohealyx and PermeaDerm are also gaining traction, with hospitals actively reviewing Cohealyx and early promise for PermeaDerm as a wound cover alternative. Doctors are embracing these tools for better patient outcomes, and 25 hospitals now use all three products. The company’s full-year revenue guidance has been bumped to $86–89M, and they’re now targeting cash flow breakeven and positive cash generation by Q4 2026—a major milestone driven by disciplined cost control and relentless execution. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/843c90382508a7dc